Artificial Intelligence-Enhanced Breast MRI: Applications in Breast Cancer Primary Treatment Response Assessment and Prediction
- PMID: 37493391
- PMCID: PMC10818006
- DOI: 10.1097/RLI.0000000000001010
Artificial Intelligence-Enhanced Breast MRI: Applications in Breast Cancer Primary Treatment Response Assessment and Prediction
Abstract
Primary systemic therapy (PST) is the treatment of choice in patients with locally advanced breast cancer and is nowadays also often used in patients with early-stage breast cancer. Although imaging remains pivotal to assess response to PST accurately, the use of imaging to predict response to PST has the potential to not only better prognostication but also allow the de-escalation or omission of potentially toxic treatment with undesirable adverse effects, the accelerated implementation of new targeted therapies, and the mitigation of surgical delays in selected patients. In response to the limited ability of radiologists to predict response to PST via qualitative, subjective assessments of tumors on magnetic resonance imaging (MRI), artificial intelligence-enhanced MRI with classical machine learning, and in more recent times, deep learning, have been used with promising results to predict response, both before the start of PST and in the early stages of treatment. This review provides an overview of the current applications of artificial intelligence to MRI in assessing and predicting response to PST, and discusses the challenges and limitations of their clinical implementation.
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
Conflicts of interest and sources of funding: K.P. received payment for activities not related to the present article including lectures including service on speakers bureaus and for travel/accommodations/meeting expenses unrelated to activities listed from the European Society of Breast Imaging, IDKD 2019, Bayer, Siemens Healthineers, and Olea Medical, and is a consultant for Merantix Healthcare and AURA Health Technologies GmbH. J.T. received payment for activities not related to the present article including lectures and travel/accommodation/meeting expenses. The rest of the authors declare no potential competing interests. The project was supported by the NIH/NCI Cancer Center Support Grant (P30 CA008748). E.M. and J.T. were funded by an institutional grant provided by the Netherlands Cancer Institute. The funding sources were not involved in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. J.H. was supported by the Breast Cancer Research Foundation.
Figures
References
-
- Cardoso F Kyriakides S Ohno S, et al. . Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30:1194–1220. - PubMed
-
- Fisher B Bryant J Wolmark N, et al. . Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–2685. - PubMed
-
- King TA, Morrow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol. 2015;12:335–343. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
